ATE257713T1 - Verwendung lebender abgeschwächter bakterien zur herstellung eines submukosalen impstoffes - Google Patents

Verwendung lebender abgeschwächter bakterien zur herstellung eines submukosalen impstoffes

Info

Publication number
ATE257713T1
ATE257713T1 AT00200216T AT00200216T ATE257713T1 AT E257713 T1 ATE257713 T1 AT E257713T1 AT 00200216 T AT00200216 T AT 00200216T AT 00200216 T AT00200216 T AT 00200216T AT E257713 T1 ATE257713 T1 AT E257713T1
Authority
AT
Austria
Prior art keywords
vaccine
submucosal
live
produce
bacteria
Prior art date
Application number
AT00200216T
Other languages
English (en)
Inventor
Antonius Arnoldus Chris Jacobs
Danny Goovaerts
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Application granted granted Critical
Publication of ATE257713T1 publication Critical patent/ATE257713T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/82—Viral vaccine for equine species, e.g. horses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/829—Bacterial vaccine for equine species, e.g. horses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT00200216T 1999-01-26 2000-01-20 Verwendung lebender abgeschwächter bakterien zur herstellung eines submukosalen impstoffes ATE257713T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99200202 1999-01-26

Publications (1)

Publication Number Publication Date
ATE257713T1 true ATE257713T1 (de) 2004-01-15

Family

ID=8239828

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00200216T ATE257713T1 (de) 1999-01-26 2000-01-20 Verwendung lebender abgeschwächter bakterien zur herstellung eines submukosalen impstoffes

Country Status (10)

Country Link
US (2) US20040120970A1 (de)
EP (1) EP1023903B1 (de)
JP (1) JP4339978B2 (de)
AT (1) ATE257713T1 (de)
AU (1) AU761515B2 (de)
CA (1) CA2296965A1 (de)
DE (1) DE60007668T2 (de)
DK (1) DK1023903T3 (de)
ES (1) ES2214217T3 (de)
PT (1) PT1023903E (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9023366B2 (en) 2003-07-01 2015-05-05 The Royal Veterinary College Vaccine composition for vaccinating dogs against canine infectious respiratory disease (CIRD)
GB0315323D0 (en) 2003-07-01 2003-08-06 Royal Veterinary College Vaccine composition
EP2172226A4 (de) 2007-06-29 2010-06-30 Stelic Institute Regenerative Medicine Verfahren zur fixierung und zur expression einer physiologisch aktiven substanz
GB0801326D0 (en) * 2008-01-24 2008-03-05 Animal Health Trust Vaccines
KR101210082B1 (ko) * 2010-10-15 2012-12-07 주식회사 동방 돼지 다발성 장막염 예방용 백신 조성물 및 그 제조방법
KR101694676B1 (ko) * 2015-12-10 2017-01-10 우진 비앤지 주식회사 말 선역 질병원인 국내 분리 스트렙토코커스 이콰이 균주 및 이를 포함하는 백신
BR112021002417A2 (pt) 2018-08-10 2021-05-04 Meiji Seika Pharma Co., Ltd. preparação de bacteriófago
CN112973157A (zh) * 2021-02-04 2021-06-18 广西田东锦盛化工有限公司 一种用于氯碱生产的盐水浓缩装置
CN113244664A (zh) * 2021-05-12 2021-08-13 伍俊雄 一种用于疫苗破乳及分离的装置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2033223B (en) * 1978-09-01 1983-09-14 Secr Social Service Brit Antigen fromstreptococcus mutans for protection against dental caries
JPS6037734B2 (ja) 1978-10-12 1985-08-28 住友電気工業株式会社 管状臓器補綴材及びその製造方法
DE3263103D1 (en) 1981-06-19 1985-05-23 Secr Social Service Brit Protection against dental caries
IE940698L (en) 1984-04-05 1985-10-05 Univ Missouri Vaccine and serum for endotoxin associated disease and method of preparing same as well as to methods of immunization and treatment of such disease and to a detoxified endotoxin and bacterial mutant
AR241545A1 (es) * 1985-07-12 1992-08-31 Cornell Res Foundation Inc Un metodo para preparar una cepa de s. equi avirulenta a.t.c.c. 53186 para equinos.
BE1008103A3 (fr) 1994-04-22 1996-01-16 Pantochim Sa Procede de preparation de catalyseurs au vanadium et phosphore et leur utilisation pour la production d'anhydride maleique.
ZA97452B (en) * 1996-01-25 1997-08-15 Trinity College Dublin Streptococcus equi vaccine.
US5895756A (en) 1997-04-11 1999-04-20 The Board Of Trustees Of The University Of Texas System Non-antibiotic system for selection of recombinant mycobacteria
US6682745B1 (en) * 1998-07-28 2004-01-27 Christiaan Antonius Arnoldus Jacobs Use of bacterium for manufacture of a vaccine
CA2243730C (en) * 1997-07-29 2009-12-22 Akzo Nobel N.V. Streptococcus equi vaccine
US6344201B1 (en) 1998-03-31 2002-02-05 Anthony T. Maurelli Methods of identifying bacterial genes that are incompatible with bacterial pathogenicity, and the use of such genes, such as cadA, to reduce pathogenicity in a bacteria or to combat pathogenic bacterial infections

Also Published As

Publication number Publication date
EP1023903B1 (de) 2004-01-14
JP2000309542A (ja) 2000-11-07
JP4339978B2 (ja) 2009-10-07
ES2214217T3 (es) 2004-09-16
US20110123571A1 (en) 2011-05-26
DE60007668D1 (de) 2004-02-19
PT1023903E (pt) 2004-04-30
EP1023903A1 (de) 2000-08-02
AU761515B2 (en) 2003-06-05
DE60007668T2 (de) 2004-12-02
US20040120970A1 (en) 2004-06-24
CA2296965A1 (en) 2000-07-26
DK1023903T3 (da) 2004-05-10
US8084040B2 (en) 2011-12-27
AU1355700A (en) 2000-07-27

Similar Documents

Publication Publication Date Title
ATE378403T1 (de) Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern
DE60141706D1 (de) Verbindungen mit fungizider wirkung und verfahren zur ihrer herstellung und verwendung
ATE457970T1 (de) Zusammensetzungen zur beseitigung von unangenehmen gerüchen
DE69526854D1 (de) Physikalisch modifizierte abbaubare thermoplastische zusammensetzung
ATE248599T1 (de) Verwendung von xenon zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von neurovergiftungen
DE69923500D1 (de) Verfahren zur Herstellung von Fluorkautschukzusammensetzungen
DE60114865D1 (de) Heterologe herstellung von polyketiden
NO20004978D0 (no) Semi-syntetiske ecteinascidiner
DE69106586D1 (de) Verwendung von Baclofen zur Herstellung von Arzneimitteln zur Behandlung von Angina pectoris.
ATE257713T1 (de) Verwendung lebender abgeschwächter bakterien zur herstellung eines submukosalen impstoffes
ID26055A (id) Senyawa-senyawa hidroksidifenil eter
CY1113261T1 (el) Διαδικασια για την παρασκευη εναντιομερικως καθαρων 1- υποκατεστημενων-3-αμινοαλκοολων
ATE380816T1 (de) Substituierte imidazopyrimidine zur prävention und behandlung von krebs
PT1112747E (pt) Vacina de salmonella que nao induz anticorpos contra flagelina ou flagelos
ATE231131T1 (de) Verbindungen mit wachtumshormon freisetzenden eigenschaften
CY1105721T1 (el) Δερματικοι αναισθητικοι παραγοντες
ATE209914T1 (de) Verwendung von pyridylmethylsulfinyl-1h- benzimidazol derivaten zur behandlung durch helicobacter verursachter erkrankungen
ATE307214T1 (de) Verfahren zur herstellung einer aus pflanzen stammenden, antibakteriellen substanz
DE69924741D1 (de) Verwendung einer zusammensetzung zur herstellung eines arzneimittels zur vorbeugung und behandlung von parodontitis
ATE270112T1 (de) Streptococcus equi impfstoff
ATE504309T1 (de) Verwendung von oxytocin zur herstellung einer pharmazeutischen zusammensetzung gegen karzinom in situ und zervizitis
DE60224884D1 (de) Verfahren zur herstellung von 3, 3', 6, 6'-tetraalkylen-2, 2'-biphenolen und 3, 3', 6, 6'-tetraalkylen-5, 5'-dihalo-2, 2' biphenolen
ATE347905T1 (de) Lebende attenuierte bakterien zur verwendung als impfstoff
DE50115225D1 (de) Verfahren zur Herstellung von Beta-Hydroxyalkylamiden
DE69715733D1 (de) Verfahren zur Herstellung von 5-Brom-2-Fluorbenzolboronsäure

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1023903

Country of ref document: EP

REN Ceased due to non-payment of the annual fee